Daewoong's COVID drug PO has cut the time to improve respiratory symptoms of patients aged 50 or older by half compared to placebo.

Daewoong announced the results of Topline in clinical 2b of Coviblock (Camostat), which is being developed as a treatment for COVID-19. Clinical trials were conducted in 24 institutions from February to July this year for 342 patients with mild COVID. The main evaluation variable is the "time it took for clinical symptoms to improve. Other key evaluation variables are 'safety' and 'worsened proportions of patients'.

Clinical symptoms include fever, cough, difficulty breathing, chills, muscle aches, headaches, and sore throat, and the degree of symptoms (0-3)